UNITED STATES
SECURITIES AND EXCHANGE
COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13
OR 15(d) of
The Securities Exchange
Act of 1934
Date of Report (Date of earliest event reported) December 17, 2008
| AspenBio Pharma, Inc. | |
| (Exact name of registrant as specified in charter) |
| Colorado | 001-33675 | 84-155338 |
|---|---|---|
| (State or other jurisdiction of incorporation) | (Commission File Number) | (IRS Employer Identification No.) |
| 1585 South Perry Street, Castle Rock, CO | 80104 |
|---|---|
| (Address of principal executive offices) | (Zip Code) |
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
| o | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| o | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| o | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| o | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
On December 17, 2008, the Registrant issued a press release titled; “AspenBio Receives Patent Office Notice of Allowance for Appendicitis Diagnostic Methods”. A copy of this press release is attached hereto as Exhibit 99.1.
| Exhibit No. |
Description |
| 99.1 | Press release dated December 17, 2008 titled, “AspenBio Receives Patent Office Notice of Allowance for Appendicitis Diagnostic Methods” |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| AspenBio Pharma, Inc. (Registrant) |
||
|---|---|---|
| Date: December 17, 2008 | By: | /s/ Jeffrey G. McGonegal |
| Jeffrey G. McGonegal | ||
| Chief Financial Officer |